Kornimate/medical-research-clean huggingface dataset:
octa (optical coherence angiography tomography) versus structural oct(optical coherence tomography) in neovascular amd (age macular degeneration)

Conditions: Macular Degeneration Exudative Eye Left; Macular Degeneration Exudative Eye Right

Summary: the objective is to find if there is a relationship between the fractal dimension, the gap, vascular density (vd), the surface, the span ratio and the status of the choroidal neovessels to adjust the interval between 2 intravitreal injections nor on the qualitative aspect of optical coherence structural tomography but also on quantified quantitative and objective values.

this quantification is based on the analysis of fractal dimension (fd, without unit), lacunarity (lac, without unit), vascular density (vd,%) and surface area of choroidal neovascular ( cnv, mm2). the fractal dimension of a vascular structure corresponds to its degree of complexity. fractals are models found in nature and biological systems that show self-similarity at different magnifications. it is obtained from the "box counting" method calculating the number of vascular segments contained in squares of varied size. normal retinal vessels have a known and quantified complexity (fd = 1.7). a neovascular tumor treated with anti-angiogenics will reduce vascular density, losing its random architecture; the investigators observe a return to a model standardized. nvcs have a random organization. the lower the fd, the more random the vascular architecture. lacunarity represents the texture or the homogeneity of a lesion, this one is heterogeneous when it is little vascularized and homogeneous if the vascularization is very dense. the lower the lake, the more homogeneous the lesion. fd and lac are obtained in angiography optical coherence tomography (octa) by the analysis of the hypersignal detected on the cut of the external retina. the image is automatically binarised and skeletonized. nvc delineation is automatic and associated with automatic background noise processing. this software is fully automatic whose inter and intra grader reproducibility will be evaluated.

Eligibility criteria:
inclusion criteria: * man / woman over 50, * showing type 1 or type 2 cnv (choroidal neovessel) related to amd during the second year of follow-up. * acceptance to participate in the protocol * affiliated to a social security scheme exclusion criteria: * type iii cnv related to amd, * other cause of cnv * signal less than 80 decibel and detachment of pigment epithelium (ped) greater than 250 μm on structural oct b. * protected majors (guardianship, curator, safeguard of justice) * participation in another interventional research. * refusal to participate in the study
identification of gestational diabetes mellitus related urinary biomarkers along pregnancy (from early pregnancy to postpartum) by using proteomics and metabolomics analysis

Conditions: Gestational Diabetes Mellitus

Summary: gestational diabetes mellitus (gdm) has many adverse effects on pregnant women and fetuses. at present, no prediction marker for gdm in early pregnancy is accepted. there is still a lack of recognized early predictors. this study was designed to identity valuable biomarkers for gdm.this was a prospective observed cohort study. 140 pregnant women were recruited in early pregnancy, and followed up to 6 weeks postpartum. glucose challenge test and 75g oral glucose tolerance test were performed after 24 weeks of pregnancy, and gdm was diagnosed according to the latest ada standard. urinary samples were collected in the first (\<12 weeks), second (24\~28 weeks) and third (32\~weeks) trimester of pregnancy. urinary proteomics and metabolomics were analyzed by ultra-performance liquid chromatography tandem mass spectrometry. 15 cases of gdm women and 50 cases of control women were used for longitudinal analysis; 15 cases of gdm women and 15 cases of age matched control women were used for difference analysis.


Eligibility criteria:
inclusion criteria: -pregnant women （\<12 weeks） exclusion criteria: * with renal dysfunction * urine routine examination abnormalities for twice * history of urinary and reproductive system diseases * with other chronic diseases

Keywords: proteomics metabolomics
eniluracil and surgery in treating patients with primary or metastatic colorectal cancer

Conditions: Colorectal Cancer

Summary: rationale: eniluracil may increase the effectiveness of chemotherapy by blocking tumor enzymes that break down chemotherapy drugs. purpose: randomized phase ii trial to determine the effectiveness of eniluracil followed by surgery in treating patients who have primary or metastatic colorectal cancer.

objectives: i. determine the enzymatic activity of dihydropyrimidine dehydrogenase (dpd) in peripheral blood mononuclear cells (pbmc), normal mucosa, or normal liver in patients with primary or metastatic colorectal cancer. ii. evaluate the ability of eniluracil to inactivate dpd in the tumor, pbmcs, and normal tissue in this patient population. iii. assess dpd recovery and uracil levels in pbmcs following surgical resection in these patients. outline: this is a randomized, placebo controlled study. patients are stratified according to colorectal tumor (primary vs metastatic). patients are randomized into one of two treatment arms. arm i: patients receive oral eniluracil twice daily on days -2 and -1 followed by surgical resection and tissue harvest on day 0. arm ii: patients receive an oral placebo as in arm i followed by surgical resection and tissue harvest on day 0. patients are followed weekly for 1 month. projected accrual: a total of 20 patients (10 per treatment arm) will be accrued for this study.

Eligibility criteria:
inclusion: 1. disease characteristics: histologically proven or suspicious primary or metastatic colorectal carcinoma undergoing disease resection 2. patient characteristics:a. age: 19 and over 3. performance status: karnofsky 60-100% 4. not pregnant or nursing fertile patients must use effective contraception during and for at least 1 month after study 5. prior concurrent therapy: 6. subject has had at least 8 weeks since prior fluorouracil, capecitabine, fluorouracil-uracil, floxuridine, or s-1 endocrine therapy: 7. no prior or concurrent steroids radiotherapy: 8. surgery: no prior emergent surgery (e.g., perforation or obstruction) no prior transplantation 9. at least 8 weeks since any prior drug metabolized by dihydropyrimidine dehydrogenase enzyme at least 8 weeks since prior flucytosine exclusion: 1. severe infection(white blood cell count)wbc\>2 times normal 2. fever 3. sepsis 4. subject on immunosuppressives therapy 5. subjects will serum bilirubin/creatinine\>2 times normal levels 6. pregnant /lactating women 7. subjects that have received eniluracil or 5-fu(fluorouracil) within 28 days prior to randomization 8. subject that have comorbidity illnesses that will increase the likelihood of there death in \<5 years

Keywords: stage i colon cancer stage ii colon cancer stage iii colon cancer stage iv colon cancer stage i rectal cancer stage ii rectal cancer stage iii rectal cancer stage iv rectal cancer recurrent colon cancer recurrent rectal cancer
assess the mid-term performance of the mpact cup in subjects requiring total hip arthroplasty

Conditions: Hip Osteoarthritis

Summary: monitor the performance of the mpact cup in the treatment of patients with hip joint disease requiring a total hip replacement.


Eligibility criteria:
inclusion criteria: * patients who are willing and able to provide written informed consent for participation in the study. written informed consent must be obtained prior to the patient's surgery. * those presenting with disease that meets the indications for use for medacta usa implants defined by this study (on-label use). * patients must be willing to comply with the pre and post-operative evaluation schedule exclusion criteria: * those with one or more medical conditions identified as a contraindication defined by the labeling on any medacta implants used in this study.
effects of growth hormone on exercise capacity

Conditions: Chronic Heart Failure

Summary: the purpose of this study was to assess whether growth hormone(gh)improves exercise capacity and cardiopulmonary performance in patients with chronic heart failure.

clinical studies have focused the effects of gh on left ventricular function and hemodynamics. little is known about the impact of gh on cardiopulmonary performance and exercise capacity. such data would be relevant, given the well-recognized importance of cardiopulmonary performance and exercise capacity as markers of disease progression and predictors of mortality in patients with chf.consequently we conducted a randomised double blind placebo controlled trial to investigate the effects of a three month course of gh, adjunctive to background therapy, on cardiopulmonary performance and exercise capacity in patients with dilated cardiomyopathy and chf.the primary outcome of the study was improvement of peak vo2 assessed by a cardiopulmonary exercise testing. secondary endpoints were exercise capacity and ejection fraction obtained by echocardiography.

Eligibility criteria:
inclusion criteria: * ejection fraction \< 40% * left ventricular internal dimension \>58 mm * ii-iii nyha class * stable hemodynamic condition during the previous three months * sinus rhythm exclusion criteria: * ima or cabg or ptca in the previous six months * instable angina * major arrhythmias (lown class\> iv) * diseases limiting exercise capacity * insulin treated diabetes mellitus

Keywords: chronic heart failure cardiopulmonary exercise oxygen consumption growth hormone
impact of nutrition intervention on hiv/aids infected patients

Conditions: Human Immunodeficiency Virus (HIV); Acquired Immune Deficiency Syndrome (AIDS)

Summary: intervention to investigate the efficacy of a nutritional supplement among arv-naïve, asymptomatic hiv positive patients with a cd4 count in the range 300-550 cells/ul.

to investigate the efficacy of a nutritional supplement among arv-naïve, asymptomatic hiv positive patients with a cd4 count in the range 300-550 cells/ul. a total of 120 participants will be stratified by age and gender and randomly assigned to two treatment arms. sixty (60) participants will be assigned to receive dietary counselling and a multivitamin/mineral supplement, with sixty (60) additionally receiving an oral medical nutritional supplement (mns). participants will be followed for six months post-randomization: at baseline, 3 months and 6 months. the principal outcome measure is body mass index, used as a proxy for 'nutritional status'. secondary outcome measures include immune status and antioxidant status.

Eligibility criteria:
inclusion criteria: * hiv positive individuals in the age range 18 to 50 years. * individuals whose cd4 count was between 300-550 cells/ul. * individuals who met the study criteria and were interested in being enrolled. * individuals not on arv therapy. * women who were not pregnant. exclusion criteria: * on the clinician's advice, individuals could be excluded from enrollment. * individuals who were unable to carry out the study intervention e.g. homeless, impaired mental state etc. * individuals who were unlikely to complete follow-up based on pre-enrolment assessment.

Keywords: hiv/aids nutrition therapy dietary supplement antioxidant immunity cd4 count anthropometry body mass index
topical nitric oxide trial in chronic non-healing wounds

Conditions: Chronic Ulcer of Lower Extremity

Summary: to determine the effects of topically applied vianox-h for 8 hours daily for 2 weeks on the reduction of the bio-burden in biofilms on chronic non-healing wounds as recorded by measurements of wound size and wound culture.

the primary goal of this study is to determine the effects of topically applied gaseous nitric oxide on the bio-burden of chronic non-healing wounds of the lower extremities. reports will include: * comparisons of the demographics and diagnoses of those patients treated with vianox-h. * tabulation as to the organisms found and the bio-burden as measured by counts (0 to +4). * tabulation of the number and types of adverse events during vianox-h treatment. * comparisons of the response of different organisms to vianox-h treatment.

Eligibility criteria:
inclusion criteria: * have a chronic (\> 8 weeks duration) colonized cutaneous ulcer (defined as a wound containing a local margin of erythema, edema or tenderness; presence of exudates; and/or presence of a malodorous smell)in their lower extremity (below the knee) resulting from either diabetes or venous stasis disease. * are 18 years of age or older. exclusion criteria: * have had a change in their topical treatment during the last 4 weeks * have evidence of clinical infection * have a transcutaneous oxygen tension \<30mmhg * have evidence of the ulcer or infection extending to the underlying muscle or bone. * are pregnant. * are less than 18 years of age.

Keywords: chronic cutaneous ulcers nitric oxide topically applied biofilm colonized chronic non-healing ulcers
a study of ganfort versus duotrav in patients with primary open angle glaucoma or ocular hypertension

Conditions: Ocular Hypertension; Primary Open Angle Glaucoma

Summary: this is a single-center, cross-over comparison parallel group randomized trial designed to evaluate the efficacy and safety of ganfort compared to duotrav for a treatment period of 8 weeks each.


Eligibility criteria:
inclusion criteria: 1. visual acuity 6/60 or better 2. patients who are controlled (iop \< 21 mmhg) on non-fixed combination of latanoprost \& timolol for at least 3 months before the baseline visit and 3. patients on mono-therapy either latanoprost or timolol who are eligible for dual therapy being not satisfactorily controlled (iop\>21mmhg) exclusion criteria: 1. angle closure glaucoma 2. neovascular galucoma 3. secondary open angle glaucoma 4. ocular infection/inflammation within 3 months 5. ocular surgery within 3 months 6. history of refractive surgery 7. argon laser trabeculoplasty/selective laser trabeculoplasty 8. pregnancy/nursing 9. hypersensitivity to benzalkonium chloride or to any other components of the trial drugs solution. 10. patients in whom beta-blockers are contraindicated 11. patients on any drugs known to affect iop.
evaluation of sp resistance and effectiveness of iptp in nigeria

Conditions: Pregnancy Complications Parasitic

Summary: the study has two components: component a is a cohort study to determine the in vivo efficacy of sp to clear and prevent malaria parasitaemia in asymptomatic pregnant women and component b is a cross sectional study of women delivering at the study hospitals to assess the effectiveness of sp-iptp to reduce adverse maternal and birth outcomes in the current context of increasing sp resistance. results of component a and b studies will be used to model the relationship between the prevalence of molecular markers of sp resistance, in vivo efficacy to clear parasite and the effectiveness of sp-iptp and to develop guidelines for routine monitoring effectiveness of sp-iptp as part of anc surveillance.

study sites will include different levels of transmission and social factors affecting anc attendance damboa hospital in borno state has a catchment area with pop of 231,573 with a semi arid climate and where malaria is mesoendemic. the expected number of patients is 15-25 per week for new bookings park lane hospital serves a semiurban population. malaria transmission is holoendemic and stable. 1400 women attend anc services per month women will receive sp-iptp according to national guidelines and will be followed for 42 days to assess the therapeutic efficacy in parasitaemic women and to assess the ability to remain parasite free. pcr will be used to determine reinfection from recrudescence

Eligibility criteria:
inclusion criteria: * gestational age 16-30 weeks * axillary temperature ,37.5 degrees * informed consent exclusion criteria: * gravida \> 2 * previous inclusion in this study * history of hypersensitivity to sp or components of sp * use of iptp with sp during this pregnancy * history of taking other antimalarials in the past month * known hiv infection

Keywords: malaria pregnancy prevention treatment molecular markers
effect of bupivacaine application on postthyroidectomy pain

Conditions: Thyroid Disease; Analgesia

Summary: investigators aimed to evaluate the impact of bupivacaine administration into the surgical field after total thyroidectomy on post-operative pain and analgesic requirement with a double-blind, prospective, clinical, randomized study. pain assessment was performed with the visual analog score (vas). participants were pre-operatively, divided into two groups randomly to receive either bupivacaine or not. one group received a 10 ml of bupivacaine solution while the other group was treated with the same volume of 0.9% sodium chloride (nacl) through the drain after completion of total thyroidectomy procedure. all participants were anesthetized and operated with the same anesthesia and surgical team.


Eligibility criteria:
inclusion criteria: * subjects need to be operated for thyroid diseases exclusion criteria: * history of previous thyroid disease, * history of previous neck operations, * hypersensitivity to the drugs that were used in the study protocol, * spinal bone disease, * depression, * kidney failure, * heart failure, * liver failure, * pulmonary failure, * mental retardation, * subjects not able to ascertain pain scoring with the visual analog score (vas), * patients with american society of anesthesiologists (asa) scores iii or higher, * expected airway difficulty according to mallampati scores, * sedative, steroid, and chronic analgesic drug users, * alcoholics
functional task kinematic in musculoskeletal pathology.

Conditions: Musculoskeletal Disease

Summary: the aim of this project is to create references values to patients with musculoskeletal pathology using functional tasks and measuring with a smartphone and video imaging (3d motion capture cameras).

musculoskeletal pathologies can affect bones, muscles, joints and other structures related to this system. these disorders are extremely common and can have an origin from autoimmune, inflammatory, traumatic, etc. the risk of developing this pathologies increases with age. the diagnosis could delayed by lack of information, expensive assessment or difficult execution. currently, you can use a smartphone to get the same information as sensors. in addition to smartphone, 3d motion capture systems with a camera have been frequently used to analyse kinematics and are being integrated as a rehabilitation tool in patients. the use of smartphones and 3d motion capture cameras would help to find fast and cheap assessment methods for professionals.

Eligibility criteria:
inclusion criteria: * persons with diagnosis of musculoskeletal pathology. * age between 20-65 años. * subjects able to get up from the chair at least 5 times. * be able to complete questionnaires and perform functional tasks. exclusion criteria: * subjects who are participating in a study with an experimental treatment. * severe cardiovascular disease. * being pregnant, in case of women.

Keywords: musculoskeletal pathology motion sensor motion capture functional task biomarker
study of intravenous gmi-1070 in adults with sickle cell disease

Conditions: Sickle Cell Disease

Summary: this phase 1/phase 2 study will evaluate gmi-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. the study will assess safety, pharmacokinetics, and microvascular effects of intravenous gmi-1070 in the outpatient setting.


Eligibility criteria:
inclusion criteria: * age 18 to 45 years * established diagnosis of scd-ss or scd-sb0-thal * at medical baseline, with no evidence of worsening of disease over the last 3 months * available and agree to return for follow-up visits for the full duration of the study * able to cooperate with study procedures * documented and observed written informed consent exclusion criteria: * vaso-occlusive crisis * recent major surgery, hospitalization, infection, significant bleeding, cerebrovascular accident or seizure, or transfusion * currently receiving, or has received within the previous 4 weeks, any other investigational agent * pregnant or lactating female; or female of childbearing age unable or unwilling to comply with birth control or abstinence during the course of the study

Keywords: sickle cell disease
adipocytokines in endometrial cancer

Conditions: Endometrial Cancer

Summary: endometrial cancer incidence rates were increasing in the past two decades with a continuous rising trend in taiwan. uterine cancer was attributable to obesity based on their association with excess body weight in most epidemiological cohort studies. however, the prevalence of obesity was lower in taiwan.therefore, we will study if adipose tissues depots in different locations of body could reflect or correlate the pathogenesis of endometrial cancer.

besides lipid metabolism, adipose tissue plays import roles in regulation of hormones, adipokines, cytokines and immunocytes. adipose tissue is now known as endocrine organ which to express and secrete a variety of bioactive peptides, known as adipokines. we will evaluate the difference various adipocytokines between visceral and subcutaneous adipose tissues between women with benign lesions and endometrial cancer. we will study the inter-individual differences in adipocytokines between two types of adipose tissues and their correlation with image quantification.

Eligibility criteria:
inclusion criteria: women diagnosed with primary endometrial cancer and undergo surgery, with or without adjuvant therapy in our hospital (emca group); women received surgery for benign pelvic lesions in our hospital (control group) exclusion criteria: women with an underlying malignancy or any concomitant malignancy, prior chemotherapy or radiation before diagnosis of endometrial cancer, history of autoimmune diseases or immunosuppressive agent use

Keywords: obesity inflammation adiponectin endometrial cancer
safety study of escitalopram in children 7 to 11 years of age with major depressive disorder

Conditions: Major Depressive Disorder

Summary: this study will evaluate the long-term safety and tolerability of escitalopram (lexapro) in children 7 to 11 years of age with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * male or female outpatients 7 to 11 years of age, inclusive * current diagnosis of mdd based on dsm-iv-tr (diagnostic and statistical manual of mental disorders, fourth edition, text revision) criteria as confirmed by k-sads-pl (kiddie schedule for affective disorders and schizophrenia-present and lifetime) with a minimum duration of 6 weeks * patient's parent(s), guardian(s), or lar(s) is capable of providing information about his or her condition, provides informed consent, and agrees to accompany the patient to all study visits. (preferably the same parent, guardian, or lar will accompany the patient to all study visits) * patient's family is sufficiently organized and stable to guarantee adequate safety monitoring exclusion criteria: * current principal dsm-iv-tr-based diagnosis of an axis i disorder other than mdd that was the primary focus of treatment * patients with a diagnosis of conduct disorder will not be allowed to participate in this study * current diagnosis of mental retardation, dementia, or amnestic or other cognitive disorders based on dsm-iv-tr criteria * history of allergy, intolerance, or hypersensitivity to escitalopram, citalopram, or other drugs of the same class * imminent risk of injuring self or others or causing significant damage to property, as judged by the pi * suicide risk as determined by meeting any of the following criteria: * any suicide attempt * significant risk, as judged by the pi, based on the psychiatric interview or information collected in the columbia-suicide severity rating scale (c-ssrs)

Keywords: depression major depressive disorder escitalopram lexapro pediatric